DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Kaseb AO, Shindoh J, Patt YZ. et al.
Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma.
Cancer 2013;
119 (18) 3334-3342
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.